JPMorgan Chase & Co’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $50.9M | Sell |
1,413,512
-21,536
| -2% | -$776K | ﹤0.01% | 1198 |
|
|
2025
Q1 | $44.7M | Buy |
1,435,048
+39,806
| +3% | +$1.24M | ﹤0.01% | 1229 |
|
|
2024
Q4 | $35.6M | Buy |
1,395,242
+105,824
| +8% | +$2.7M | ﹤0.01% | 1352 |
|
|
2024
Q3 | $36.5M | Sell |
1,289,418
-6,449,863
| -83% | -$182M | ﹤0.01% | 1356 |
|
|
2024
Q2 | $204M | Sell |
7,739,281
-255,818
| -3% | -$6.75M | 0.02% | 607 |
|
|
2024
Q1 | $243M | Sell |
7,995,099
-705,220
| -8% | -$21.4M | 0.02% | 557 |
|
|
2023
Q4 | $244M | Sell |
8,700,319
-187,248
| -2% | -$5.26M | 0.02% | 520 |
|
|
2023
Q3 | $241M | Buy |
8,887,567
+151,396
| +2% | +$4.11M | 0.03% | 474 |
|
|
2023
Q2 | $269M | Buy |
8,736,171
+64,608
| +0.7% | +$1.99M | 0.03% | 453 |
|
|
2023
Q1 | $312M | Buy |
8,671,563
+246,816
| +3% | +$8.89M | 0.04% | 375 |
|
|
2022
Q4 | $333M | Buy |
8,424,747
+93,150
| +1% | +$3.68M | 0.04% | 350 |
|
|
2022
Q3 | $335M | Buy |
8,331,597
+683,612
| +9% | +$27.5M | 0.05% | 339 |
|
|
2022
Q2 | $322M | Buy |
7,647,985
+2,088,597
| +38% | +$87.8M | 0.04% | 354 |
|
|
2022
Q1 | $217M | Buy |
5,559,388
+137,185
| +3% | +$5.34M | 0.03% | 510 |
|
|
2021
Q4 | $216M | Buy |
5,422,203
+105,721
| +2% | +$4.21M | 0.03% | 505 |
|
|
2021
Q3 | $192M | Sell |
5,316,482
-1,998,519
| -27% | -$72.2M | 0.02% | 553 |
|
|
2021
Q2 | $300M | Buy |
7,315,001
+1,519,734
| +26% | +$62.3M | 0.04% | 454 |
|
|
2021
Q1 | $253M | Sell |
5,795,267
-285,092
| -5% | -$12.4M | 0.03% | 473 |
|
|
2020
Q4 | $304M | Buy |
6,080,359
+2,329,123
| +62% | +$117M | 0.04% | 378 |
|
|
2020
Q3 | $158M | Buy |
3,751,236
+27,312
| +0.7% | +$1.15M | 0.03% | 509 |
|
|
2020
Q2 | $181M | Buy |
+3,723,924
| New | +$181M | 0.03% | 449 |
|